Stocks of DexCom Inc. (NASDAQ:DXCM) traded higher last session on Wall Street, down -1.62% to $92.63.
According to the data, DexCom Inc. (NASDAQ:DXCM) has 23 analysts covering its stock. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $160.00 and a low of $130.00, we find $150.00. Given the previous closing price of $94.16, this indicates a potential upside of 59.3 percent. DXCM stock price is now -19.27% away from the 50-day moving average and -20.29% away from the 200-day moving average. The market capitalization of the company currently stands at $37.87B.
A total of 2 analysts have issued a hold rating and 17 have given it a buy rating. Brokers who have rated the stock have averaged $146.93 as their price target over the next twelve months.
In other news, ALTMAN STEVEN R, Director sold 1,000 shares of the company’s stock on Sep 15. The stock was sold for $101,495 at an average price of $101.50. Upon completion of the transaction, the Director now directly owns 61,700 shares in the company, valued at $5.72 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Sep 12, Director Heller Bridgette P sold 600 shares of the business’s stock. A total of $63,936 was realized by selling the stock at an average price of $106.56. This leaves the insider owning 23,731 shares of the company worth $2.2 million. Insiders disposed of 410,944 shares of company stock worth roughly $38.07 million over the past 1 year. A total of 0.10% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in DXCM stock. A new stake in DexCom Inc. shares was purchased by UNISUPER MANAGEMENT PTY LTD during the first quarter worth $15,450,000. CANTOR FITZGERALD, L. P. invested $14,913,000 in shares of DXCM during the first quarter. In the first quarter, BLACKSTONE INC. acquired a new stake in DexCom Inc. valued at approximately $14,821,000. COVEA FINANCE acquired a new stake in DXCM for approximately $14,163,000. HBK INVESTMENTS L P purchased a new stake in DXCM valued at around $5,564,000 in the second quarter. In total, there are 1,361 active investors with 98.80% ownership of the company’s stock.
Wednesday’s opening bell rang with an opening price of $95.37 for DexCom Inc. (NASDAQ: DXCM). During the past 12 months, DexCom Inc. has had a low of $78.94 and a high of $139.55. As of last week, the company has a debt-to-equity ratio of 1.55, a current ratio of 2.40, and a quick ratio of 2.20. According to the stock market information, the enterprise value for the company is $35.66B, which is based on a 110.54 price-to-earnings ratio, a 3.02 price-to-earnings-growth ratio, and a beta of 1.12. The fifty day moving average price for DXCM is $113.97 and a two-hundred day moving average price translates $116.08 for the stock.
The latest earnings results from DexCom Inc. (NASDAQ: DXCM) was released for Jun, 2023. According to the Medical Devices Company, earnings per share came in at $0.34, beating analysts’ expectations of $0.23 by 0.11. This compares to $0.12 EPS in the same period last year. The net profit margin was 11.20% and return on equity was 17.30% for DXCM. The company reported revenue of $871.3 million for the quarter, compared to $696.2 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 25.15 percent. For the current quarter, analysts expect DXCM to generate $938.94M in revenue.
DexCom Inc.(DXCM) Company Profile
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
